Intra-articular sustained-release of pirfenidone as a disease-modifying treatment for early osteoarthritis

Area of Science:

• Biomedical Engineering
• Orthopedics
• Pharmacology

Background:

• Osteoarthritis (OA) presents a significant clinical challenge with limited disease-modifying treatments due to complex pathology.
• Excessive transforming growth factor beta (TGFβ) drives synovial fibrosis and subchondral bone sclerosis, preceding cartilage degradation in early OA.

Purpose of the Study:

• To investigate the disease-modifying potential of intra-articular sustained-release pirfenidone (PFD), a TGFβ inhibitor, for early OA treatment.
• To develop and evaluate a novel drug delivery strategy for sustained PFD release in OA joints.

Main Methods:

• Developed a sustained-release formulation using poly lactic-co-glycolic acid (PLGA) microparticles and hyaluronic acid (HA) solution for monthly intra-articular PFD injections.
• Utilized a destabilization of the medial meniscus (DMM)-induced OA mouse model to assess the therapeutic efficacy of the PLGA-PFD + HA strategy.

Main Results:

• PFD demonstrated the ability to restore mineralization in the presence of elevated TGFβ1 levels.
• The PLGA-PFD + HA strategy effectively prevented subchondral bone loss in early OA and subchondral bone sclerosis in late OA.
• Treatment reduced synovitis and pain while preserving cartilage in the OA mouse model.

Conclusions:

• Intra-articular sustained-release PFD via PLGA-PFD + HA is a promising disease-modifying strategy for early OA.
• This approach targets key pathological pathways, including TGFβ signaling, to halt OA progression.
• PFD holds potential as a novel therapeutic agent for clinical application in osteoarthritis management.